eDoorways Corp., a web-based consumer problem-solving gateway, lifestyle information source, and online business-to-consumer marketplace, announced today that it has exceeded 20,000 followers on its Twitter campaign. The company has plans to incorporate the use of Twitter and other social media outlets as part of its initial support strategy when the SOLVE doorway version “Beta 1.0″ is released next month.

Ann Collins, SOLVE Project Manager and Social Media Consultant for the eDoorways Corporation, said, “eDoorways has impressively surpassed the 20,000 follower mark in less than three months on Twitter. Many companies are successfully using the connections they have on Twitter to better support their customer base. However, one mistake they make — one that eDoorways is certainly attempting to avoid — is to go after quantity rather than quality when it comes to their contacts.”

Twitter is a great way to gather relevant input

...

New York-based Monster Worldwide Inc. (MWW) is an online recruitment firm and the parent company of Monster.com, the leading career website in the world.

Yesterday, the company announced plans to open a new technology center of Excellence & Innovation in Cambridge, Massachusetts, and make certain organizational changes. Monster plans to add more staff to this center in the foreseeable future. As part of organizational changes, the company will eliminate approximately 160 positions within the product and technology group on a global basis.

Monster is now actively recruiting for approximately 80 new technical positions to be located in the Cambridge center, with potential capacity for adding a total of 170 new positions at this center. The company already has technological centers in Massachusetts, California, Czech Republic, Malaysia and New Delhi. Monster believes that Cambridge is a strategic location for its business.

The company‘s business has been adversely affected by

...

div style="text-align: justify;"Morgan Stanley is out with a major call onspan style="font-weight: bold;" Omniture (NASDAQ:OMTR)/span upgrading their rating to Overweight from Equal Weight and initiating a price tgt of $18.br /br /span style="font-weight: bold;"Current valuations underestimate the core cash flow growth potential:/span The dominant vendor enabling better returns on a customer’s online marketing spend, OMTR is well-positioned to be one of the strongest growers in the group. span style="font-weight: bold;"Conversations with customers indicate a pent up demand for new spending with OMTR, which should drive upside to consensus looking for just 2% billings growth in CY09, the firm estimates +6%/span. Expectations have come down materially over the past 10 months, and may now actually overestimate the impact of free offerings. More aggressive expense management — compounding the impact of stronger billings — drives 25%+ cash flow growth in Morgan Stanley model. Yet at 12.5x, OMTR trades at a 20%+ discount ...

In the latest developments of Hemispherx BioPharma, BioMedReports analyzes and dissects the latest article from TheStreet.com with an interview involving Dr. Carter. If you are an avid fan of Ampligen and have invested in Hemispherx, this read is definitely worth your time. Article published by M.E. Garza of BioMedReports.com

“What do we think CFS is?” Dr. William Reeves asked a worldwide audience watching his streaming video presentation from the meeting for the Chronic Fatigue Syndrome Advisory Committee (CFSAC) of the Department of Health and Human Services in Washington, DC. on Thursday. “It’s a complex illness, with alterations in complex homeostatic systems. It’s not the result of a single mutation or a single environmental factor. It comes from a combination of many factors: genetics, gender, stressors, immune stressors all interact.”

Reeves is chief of the U.S.

...